Protalix BioTherapeutics Inc (DE)

Financials

Total assets 67.93 M73.67 M55.79 M84.43 M73.42 M Total liabilities 94.97 M79.7 M66.43 M50.87 M30.21 M Total equity 27.04 M6.04 M10.64 M33.57 M43.21 M Total liabilities & shareholders' equities 67.93 M73.67 M55.79 M84.43 M73.42 M Total debt ————— Net debt —————

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.

PLX

Financials

Protalix BioTherapeutics Inc (DE)

Notizie

Brazil judge overrules decisions suspending changes to meal voucher system

A March Decision That Could Change Protalix’s Outlook (NYSE:PLX)

Azioni Pluxee ed Edenred in rialzo dopo risultati e prospettive positive

Pluxee, Edenred shares jump after upbeat results and outlook

Slide di presentazione del Q1 2026 di Pluxee: crescita del 9% nonostante le sfide in Brasile

Pluxee posts 9% growth in Q1; confirms 2026 outlook despite Brazil headwinds

Pluxee registra una crescita del 9% nel Q1; conferma le prospettive per il 2026 nonostante le difficoltà in Brasile

Protalix delinea la strategia 2026 con focus sulla terapia per la gotta incontrollata

Tuesday’s Insider Activity: Key Execs Make Notable Trades

Dror Bashan, CEO di Protalix BioTherapeutics, acquista azioni per 101.000 dollari

BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN)

Protalix e Secarna collaborano per sviluppare trattamenti per malattie renali rare